title: Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation.
abstract: In an attempt to mimic cytokine gene-transfected tumor cells and to develop an alternative approach to cancer immunotherapy, the authors vaccinated mice with mixtures of inactivated tumor cells and cytokine-containing depots. The RenCa mouse renal carcinoma and the B16 mouse melanoma were used as animal tumor models, with interleukin-2 (IL-2) as a cytokine and liposomes as a depot form. The results obtained show that vaccines consisting of mixtures of irradiated tumor cells and cytokine-containing liposomes can be used as highly effective tumor vaccines. These vaccines are very easy to prepare and, in contrast to vaccines consisting of cytokine gene transfected tumor cells, their composition (cell dosage, cytokine dosage) can be easily varied. Vaccination efficiency depended on (a) on the immunogenicity of the tumor cells: RenCa tumor cells are more immunogenic than B16 melanoma cells; (b) vaccination frequency: a single vaccination with irradiated tumor cells and 10 micrograms of IL-2 in liposome-encapsulated form was sufficient to induce lasting protective immunity against the RenCa tumor, whereas several (four to six) vaccinations in weekly intervals were needed to obtain a similar degree of protective immunity to the B16 melanoma; and (c) the dose of the cytokine encapsulated in the admixed liposome depots: immunity to the tumors could be induced only within a narrow cytokine-dose range ("IL-2-dose window"). The results obtained indicate that, because of the easiness of preparation and handling, vaccine formulations consisting of irradiated tumor cells and IL-2 in depot formulations are candidates for tumor vaccines for the treatment of tumor patients.
authors.affiliation: Abteilung für Medizinische Mikrobiologie, Medizinische Fakultät, Ruhr-Universität Bochum, Germany.
authors.forename: O C
authors.initials: OC
authors.lastname: Krup
authors.forename: I
authors.initials: I
authors.lastname: Kroll
authors.forename: G
authors.initials: G
authors.lastname: Böse
authors.forename: F W
authors.initials: FW
authors.lastname: Falkenberg
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D003692:Delayed-Action Preparations; D016233:Immunotherapy, Active; D007376:Interleukin-2 / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D008081:Liposomes; D008546:Melanoma, Experimental / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D013154:Spleen / Q000166:cytology; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D003692:Delayed-Action Preparations; D007376:Interleukin-2; D008081:Liposomes